GlassScriptPhysician profile
Mark Vaynkhadler
NPI 1548452352
$4,761.58
in general payments reported to CMS, 2019-2025
23 companies · $807 in 2025
The $807 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $348 · 2021: $353 · 2022: $718 · 2023: $1,015 · 2024: $893 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698 · Education: $16.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.44 |
| Education | $16.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.26 | 2019-2023 | Orilissa |
| Sumitomo Pharma America, INC. | $648.21 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $537.57 | 2023-2025 | Veozah, Myrbetriq |
| Myriad Women'S Health, INC. | $470.97 | 2023 | Myrisk |
| Shield Therapeutics INC | $353.38 | 2024-2025 | |
| Coopersurgical, INC. | $280.24 | 2019-2022 | |
| Myovant Sciences INC. | $257.72 | 2021-2022 | |
| Lupin INC. | $210.08 | 2019-2020 | |
| Pfizer INC. | $193.17 | 2022-2024 | |
| Biogen, INC. | $190.74 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $173.45 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $146.49 | 2023-2025 | |
| Hologic Sales and Service, LLC | $117.81 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Evofem Biosciences, INC. | $100.90 | 2022-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $90.05 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $63.82 | 2019-2020 | |
| Exeltis, USA INC. | $58.82 | 2020-2021 | |
| Duchesnay USA Incorporated | $45.18 | 2019 | |
| Avion Pharmaceuticals | $24.83 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $18.94 | 2023 | Vivjoa |
| Virtus Pharmaceuticals LLC | $15.04 | 2021 | |
| Organon LLC | $12.62 | 2024 | |
| Mission Pharmacal Company | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vaynkhadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.